Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.01% Nasdaq Up0.31%

Galena Biopharma, Inc. (GALE)

2.34 Up 0.05(2.18%) 10:42AM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Galena Biopharma, Inc.
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States - Map
Phone: 855-855-4253

Index Membership:N/A
Full Time Employees:60

Business Summary 

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Galena Biopharma, Inc.

Corporate Governance 
Galena Biopharma, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Mark J. Ahn Ph.D., 51
Chief Exec. Officer, Pres and Director
Dr. Mark W. Schwartz Ph.D., 59
Chief Operating Officer and Exec. VP
Mr. Ryan M. Dunlap , 44
Chief Financial Officer, Principal Accounting Officer, VP and Director
Dr. Hana B. Moran Ph.D.,
VP of Regulatory Affairs and Compliance
Ms. Remy Bernarda ,
VP of Marketing & Communications
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders